Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Alyssa Walker

Physician Assistant Columbia, SC Physician Assistant

NPI 1174136816 CMS profile 11402225

8 Richland Medical Park Dr Ste 100, Columbia, SC 29203

Open in the dashboard

General payments

$4,958

204 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alyssa Walker of Columbia, SC is reported in the CMS Open Payments database as having received $4,958 across 204 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,612 59
2024 General $1,645 71
2023 General $1,700 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alyssa Walker
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Alyssa Walker were reported at $1,612. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Alyssa Walker Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $1,700 $167 $52–$557 $160
2024 $1,645 $178 $55–$600 $164
2025 $1,612 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Merck Sharp & Dohme Corporation $534 25 payments
  2. Amgen Inc. $467 23 payments
  3. E.R. Squibb & Sons, L.L.C. $396 19 payments
  4. Alnylam Pharmaceuticals Inc. $389 16 payments
  5. Pfizer Inc. $284 14 payments
  6. Philips Electronics North America Corporation $275 10 payments
  7. Novo Nordisk Inc $260 6 payments
  8. Kestra Medical Technology Services, Inc. $260 2 payments
  9. Edwards Lifesciences Corporation $189 4 payments
  10. Janssen Pharmaceuticals, Inc $185 12 payments
  11. Other $1,719 73 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $4,958 204 payments
Products named General payments · program years 2023–2025
  1. VERQUVO Cardiovascular $703 34 payments
  2. Repatha $394 19 payments
  3. ONPATTRO $389 16 payments
  4. CAMZYOS $271 10 payments
  5. Assure WCD $260 2 payments
  6. VERQUVO Cardiovascular $225 8 payments
  7. ELIQUIS $191 9 payments
  8. XARELTO $185 12 payments
  9. NURTEC ODT $176 8 payments
  10. LEQVIO $161 9 payments
  11. Other $2,675 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,340

Median for Physician Assistant: 241

Drug cost

$523,369

Median for Physician Assistant: $4,110

Branded share of claims

27.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 199 $192,268
Entresto Sacubitril/Valsartan Brand 110 $116,950
Jardiance Empagliflozin Brand 73 $79,015
Repatha Sureclick Evolocumab Brand 26 $33,531
Xarelto Rivaroxaban Brand 31 $32,863
Farxiga Dapagliflozin Propanediol Brand 28 $30,908
Brilinta Ticagrelor Brand 13 $12,434
Metoprolol Succinate Generic 271 $3,984
Atorvastatin Calcium Generic 222 $2,910
Amiodarone Hcl Generic 60 $2,637

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$13,402

Medicare's payments for the services billed

Medicare patients

139

Average age 74

Services billed

180

70 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Arthritis 50%
Heart failure 46%
Diabetes 45%
Chronic kidney disease 38%
Atrial fibrillation 37%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $258
$258 26 —
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $180
$180 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $169
$169 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $86
$86 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $38
  • PFIZER INC. $30
$67 199 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record